Fig. 1: Schematic representation of the kynurenine pathway. | Translational Psychiatry

Fig. 1: Schematic representation of the kynurenine pathway.

From: Impact of IDO activation and alterations in the kynurenine pathway on hyperserotonemia, NAD+ production, and AhR activation in autism spectrum disorder

Fig. 1

The serotonergic pathway that also branches out of TRP is indicated in grey. Metabolites are shown in black and enzymes are in blue. 3-HAO 3-hydroxyanthranilate oxidase (EC 1.10.3.5), ACMSD aminocarboxymuconate-semialdehyde decarboxylase (EC 4.1.1.45), CAT catalase (EC 1.11.1.6), IDO indoleamine 2,3-dioxygenase (EC 1.13.11.52), KAT kynurenine-oxoglutarate transaminases or kynurenine aminotransferases (EC 2.6.1.7), KMO kynurenine 3-monooxygenase (EC 1.14.13.9), KYNU kynurenine hydrolase or kynureninase (EC 3.7.1.3), NAD+ nicotinamide adenine dinucleotide, MAO-A monoamine oxidase A (E.C. 1.4.3.4), NADSYN1 glutamine-dependent NAD+ synthetase (EC 6.3.5.1), NAMPT nicotinamide phosphoribosyl transferase (EC 2.4.2.12), NAPRT nicotinate phosphoribosyl transferase (EC 6.3.4.21), NMNAT nicotinamide nucleotide adenylyl transferase (EC 2.7.7.1), PST-M monoamine-sulphating phenol sulphotransferase (EC 2.8.2.1), QPRT quinolinate phosphoribosyl transferase (EC 2.4.2.19), SOD superoxide dismutase (EC 1.15.1.1), TDO tryptophan 3,3-dioxygenase (EC 1.13.11.11). The dotted line indicates a minor reaction.

Back to article page